Haemophilia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Male people diagnosed with haemophilia A of any level of severity, who have had a history of inhibitor levels of 0.6 BU/mL or higher — including those whose previous immune tolerance induction (ITI) treatment did not work (confirm with trial site for exact inhibitor measurement details)
- People currently undergoing a specific type of treatment called immune tolerance induction (ITI) using one of three products — Nuwiq, octanate, or wilate — whether on their own or combined with one of the following additional therapies: emicizumab, activated prothrombin complex concentrate (aPCC), or activated recombinant factor VII (rFVIIa)
- People who are able to give signed consent to participate, or — for younger participants — whose parent or legal guardian is able to give that consent on their behalf
Who may not be able to join:
- People who have been diagnosed with any blood clotting disorder other than haemophilia A
- People whose participation would be partly based on past medical records, where detailed records of treatment, all bleeding episodes, inhibitor levels, and factor VIII levels are not available for that past period
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Robert Sidonio, MD, MSc, Emory University
Phone: 404-785-1637
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of participants achieving inhibitor titer < 0.6 Bethesda units (BU)/mL L for at least 2 consecutive measurements; Proportion of participants achieving FVIII recovery ≥ 66% of the predefined reference value of 1.5% IU/kg body weight (Groups 1 and 2); Proportion of participants achieving FVIII half-life ≥ 6 h (Groups 1 and 2); Annualized bleeding rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.